Outset Medical Shares Rise 56% After FDA Grants Clearance for TabloCart

By Chris Wack

Outset Medical shares were up 56% to $4.89 after the company said that the Food and Drug Administration has granted 510(k) clearance of its TabloCart with prefiltration, an optional accessory for the Tablo Hemodialysis System.

The stock hit its 52-week low of $1.92 on April 15, and is down 76% in the past 12 months.

The medical technology company said it has resumed distribution of TabloCart with prefiltration and has product available to ship to customers in the U.S.

Outset's TabloCart is designed to improve user experience within healthcare facilities. It is available in two versions: one with added storage and another featuring water prefiltration capabilities, meeting diverse clinical needs, the company says.

Write to Chris Wack at [e-mail]

(END) Dow Jones Newswires

05-06-24 1053ET